Osteoporose & Osteopetrose Gennembrud! Flere studier har vist lovende resultater med GcMAF

Flere forsøg har nu vist meget lovende resultater med et lille immun stimulerende protein ved navn GcMAF, også kendt som Glycosylated Vitamin-D Binding Protein (VDBP). For det ikke skulle være nok, så er det endda et protein som er frit tilgængeligt i håndkøb i EU.

Gcmaf fabrikeres i sunde og raske mennesker i rigelige mængder i leveren, i form af GC Globulin som derefter laves om til aktivt GcMAF ved hjælp af immunforsvarets T og B celler...men...det er kun i sunde mennesker. I mennesker med en fejl i enten leveren, B og T cellerne, mængden af GcGlobulin, mængden af hvide blodlegemer eller mennesker med et højere niveau af det immun-undertrykkende molekyle Nagalase, kan der opstå en mangel med følgevirkninger som undertrykt immunforsvar, øget modtagelighed overfor vira, infektioner og kræft. Listen er måske meget længere, når man tager i betragtning hvor mange problemer et undertrykt immunforsvar kan fører med sig, men selvom der forskes ivrigt, så er der stadig mange spørgsmål tilbage.

Hvad siger osteoporose relateret forskning om GcMAF ? * Naturlig Gcmaf aktiverer osteoclaster. Defekt Osteoklast-aktivering er netop skyld i visse knogle sygdomme. * Gcmaf stimulerer knoglevækst og øger knogle tætheden. * Gcmaf er den aktiverende faktor for både makrofager og osteoklaster. * Som følge af dens knogle opbyggende egenskab, foreslår samme studie at gcmaf kunne benyttes til behandling af osteoporose, knoglebrud, reparation af knogle defekter, ved rygmarv operationer og ved knogle udskiftninger (som hofteoperationer). * Gcmaf produceres kontinuerligt i små mængder i sunder personer, men ikke hos personer med f.eks. opetrose og man ved også at cancer patienter har problemer med Gcmaf og for højt Nagalase. * Den arvelige Osteopetrose tilstand blev normaliseret i rotte forsøg med tilførsel af gcmaf. Se de spændende studier på Osteoporose og relaterede problemer nedenfor:

1# Baculovirus-expressed vitaminD-binding protein-macrophage activating factor (DBP-maf) activates osteoclasts and binding of vitamin D(3) does not influence this activity. Summary: GcMAF regulates bone resorption (the natural breakdown of bone material) by activating osteoclasts. Defective osteoclast activation leads to bone disorders like ostoepetrosis. This study was to investigate the effect of the different types of GcMAF (natural, gene expressed or bound to Vitamin D). Natural GcMAF gave significant activation of the osteoclasts, regardless of whether it was bound to vitamin D or not. This was a higher level of activity of any other stimulators assessed. Gcprotein showed no activity, whereas GcMAF did. Swamy N, Ghosh S, Schneider GB, Ray R. . J CellBiochem. 2001;81(3):535-46. PubMed PMID: 11255236. 2# The anabolic effects of vitamin D-binding protein-macrophage activating factor (DBP-MAF) and a novel small peptide on bone.

Summary: A novel protein was synthesized to replicate the third domain of Vitamin D binding protein. GcMAF has previously been shown to stimulate bone growth and this reports that a similar, but synthetically produced, peptide has the same ability to significantly increase bone density. This report details that GcMAF and the synthetic peptide represent opportunities for a number of bone diseases and skeletal disorders. It could be used to treat osteoporosis, fractures, bony defect repairs, spinal surgery and joint replacement.

Schneider GB, Grecco KJ, Safadi FF, Popoff SN. Crit Rev Eukaryot Gene Expr. 2003;13(2-4):277-84. PMID: 14696974. 3# Lectin immunoassay for macrophage-activatingfactor (Gc-MAF) produced by deglycosylation of Gc-globulin: evidence fornoninducible generation of Gc-MAF. Summary: Three types of common Gc alleles are Gc1F, Gc1s, and Gc2, plus hundreds of less common types. Gc2 does not contain sialic acid residues. GcMAF has been shown to have a role in the activation of macrophages and in osteoclast differentiation (and thus bone remodeling). This report was to identify methods of detecting GcMAF in blood, and in which type of blood it may be deficient. The blood concentrations of normally produced in vivo GcMAF are quite low, but increased at sites of inflammation. GcMAF is produced continually in healthy adults, but is not produced in patients with recessive osteopetrosis.

Kanan RM, Cook DB, Datta HK.

Clin Chem. 2000 Mar;46(3):412-4. PubMed PMID: 10702530.

4#

Effects of vitamin D binding protein-macrophage activating factor (DBP-MAF) infusion on bone resorption in two osteopetrotic mutations.

Summary: GcMAF is deficient in the hereditary bone disease, osteopetrosis, causing a build-up of skeletal tissue and defects to the immune system. The administration of Gcmaf to newborn rats exhibiting this ailment showed the majority of osteoclasts exhibiting normal structure.

Schneider GB, Benis KA, Flay NW, Ireland RA, Popoff SN. Bone. 1995 Jun;16(6):657-62. PubMed PMID: 7669443.

5# Defective lymphocyte glycosidases in the macrophage activation cascade of juvenile osteopetrosis.

Summary: This study shows that the lack of GcMAF which is the activating factor for both macrophages and osteoclasts can be attributed to the inability of the osteopetrosis patient to generate the glycosidases which convert gcprotein to gcmaf.

Yamamoto N, Naraparaju VR, Orchard PJ. Blood. 1996 Aug 15;88(4):1473-8. PubMed PMID: 8695868.

6#

Treatment of osteoporosis, osteoarthritis, rheumatoid arthritis and periodontal disease with GcMAF.

Bone resorption by osteoclast cells is promoted by activated vitamin D-binding factor (GcMAF), thereby providing an effective treatment for osteopetrosis. Conversely, inflammation-mediated bone loss is inhibited with antibody against the activated factor, providing a treatment for inflammation-mediated osteolytic diseases such as osteoporosis, osteoarthritis, rheumatoid arthritis and periodontal disease. The antibodies are further utilized in an antigen binding assay for diagnosing inflammation-mediated bone loss.

Popoff, Steven N. (Warrington, PA) Schneider, Gary B. (Gurnee, IL) 25.7.1994

www.freepatentsonline.com/5641747.html

Other Comments: After reading all the above, some people might want to supplement with gcmaf. In addition to gcmaf, it could also be beneficial to supplem with Vitamin-D3 and K2. Calcium supplementation will not lower your risk for bone fractures, and eating and drinking dairy products will only result in a negative calcium balance! According to Thomas E. Levy, MD, JD, taking a calcium supplement is like putting a 'fresh coat of paint on a rotten fence'. You may get a "better score" on a 'bone density test' - but you will not reduce your risk of weakened bones or hip fractures. In addition, according to Dr. Levy, "you are 30% more likely to have a heart attack and up to 20% more likely to have a stroke if you take an extra 500 mg of calcium or more per day."

#osteoporose #osteoporosis #osteopetrose #gigt #rheumatoidarthritis #paradontose #osteoarthritis